We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
51
Rhythm Pharmaceuticals
RYTM
$7.38B
$17.1M 0.1%
4,125,062
– –
OPT
52
DELISTED
Opthea Limited American Depositary Shares
OPT
$17M 0.1%
2,696,191
– –
ADAP
53
DELISTED
Adaptimmune Therapeutics
ADAP
$16.7M 0.09%
9,830,877
– –
CRNX icon
54
Crinetics Pharmaceuticals
CRNX
$8.88B
$15.4M 0.09%
827,480
– –
TCDA
55
DELISTED
Tricida, Inc. Common Stock
TCDA
$14.6M 0.08%
1,503,090
-228,624
-13% -$2.18M
FMTX
56
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$14M 0.08%
2,024,876
– –
FLGT icon
57
Fulgent Genetics
FLGT
$561M
$11M 0.06%
201,444
– –
BLUE
58
DELISTED
bluebird bio
BLUE
$10.3M 0.06%
124,986
– –
RLMD icon
59
Relmada Therapeutics
RLMD
$544M
$9.4M 0.05%
495,113
– –
DICE
60
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$9.13M 0.05%
588,235
– –
ZYME icon
61
Zymeworks
ZYME
$1.62B
$9.05M 0.05%
1,708,472
– –
KRTX
62
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.85M 0.05%
69,966
– –
TCRX icon
63
TScan Therapeutics
TCRX
$48.8M
$8.76M 0.05%
2,784,792
+1,359,792
+95% +$3.72M
ANAB icon
64
AnaptysBio
ANAB
$1.54B
$8.67M 0.05%
427,179
– –
KYNB
65
Kyntra Bio
KYNB
$28.1M
$8.61M 0.05%
32,629
+9,359
+40% +$2.39M
CYT
66
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$7.9M 0.04%
2,643,640
+1,831,000
+225% +$4.68M
SRZN icon
67
Surrozen
SRZN
$215M
$7.5M 0.04%
166,667
– –
RETA
68
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.81M 0.04%
223,976
– –
ACHL
69
DELISTED
Achilles Therapeutics
ACHL
$6.53M 0.04%
2,591,366
– –
CBAY
70
DELISTED
Cymabay Therapeutics
CBAY
$6.4M 0.04%
2,170,464
– –
BCEL
71
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6.32M 0.04%
3,532,760
– –
TLIS
72
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$6.19M 0.04%
508,322
– –
HRMY icon
73
Harmony Biosciences
HRMY
$2.07B
$6.03M 0.03%
123,600
– –
ATRA icon
74
Atara Biotherapeutics
ATRA
$71.6M
$5.8M 0.03%
+29,767
New +$4.86M
VOR icon
75
Vor Biopharma
VOR
$1.1B
$5.66M 0.03%
+56,938
New +$5.83M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Baker Bros. Advisors held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Baker Bros. Advisors added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Baker Bros. Advisors's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Baker Bros. Advisors fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Baker Bros. Advisors opened 5 new positions and closed 6 in Q2 2022.
  • Baker Bros. Advisors's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.